Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study

Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy

(2021) Antonio Julià et al.   BMC MUSCULOSKELETAL DISORDERS

Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study

(2021) Yuichi Maeda et al.   RHEUMATOLOGY INTERNATIONAL

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

(2020) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sjögren’s syndrome enrolled in a large observational US registry

(2020) Leslie R. Harrold et al.   RHEUMATOLOGY INTERNATIONAL

Rheumatoid factor as predictor of response to treatment with anti-TNF alpha drugs in patients with rheumatoid arthritis

(2019) Pedro Santos-Moreno et al.   MEDICINE

Targeting FcRn to Generate Antibody-Based Therapeutics

(2018) E. Sally Ward et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Effects of Soluble Tumor Necrosis Factor (TNF) on Antibody-Dependent Cellular Cytotoxicity of Therapeutic anti-TNF-α Antibody

(2018) Haruka Hirosaki et al.   IMMUNOLOGICAL INVESTIGATIONS

Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins

(2017) Liming Liu   Protein & Cell

Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer

(2016) Charlene Porter et al.   JOURNAL OF REPRODUCTIVE IMMUNOLOGY

IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding

(2015) David Ternant et al.   JOURNAL OF IMMUNOLOGY

IgM rheumatoid factor amplifies the inflammatory response of macrophages induced by the rheumatoid arthritis-specific immune complexes containing anticitrullinated protein antibodies

(2014) Lætitia Laurent et al.   ANNALS OF THE RHEUMATIC DISEASES

The Status of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Are Not Associated with the Effect of Anti-TNFα Agent Treatment in Patients with Rheumatoid Arthritis: A Meta-Analysis

(2014) Qianwen Lv et al.   PLoS One

Rheumatoid Factors: Clinical Applications

(2013) Francesca Ingegnoli et al.   DISEASE MARKERS

Rheumatoid factor and response to TNF antagonists in rheumatoid arthritis: Systematic review and meta-analysis of observational studies

(2013) Eva Salgado et al.   JOINT BONE SPINE

A rheumatoid factor paradox: inhibition of rituximab effector function

(2013) Jonathan D Jones et al.   ARTHRITIS RESEARCH & THERAPY

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis

(2011) T. Takeuchi et al.   ANNALS OF THE RHEUMATIC DISEASES

The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study

(2011) R. Klaasen et al.   RHEUMATOLOGY

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM

Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α

(2010) Sachiko Onishi et al.   Modern Rheumatology

Certolizumab pegol for the management of Crohn's disease in adults

(2009) Anastasia Rivkin   CLINICAL THERAPEUTICS

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis

(2008) C Potter et al.   ANNALS OF THE RHEUMATIC DISEASES

A PEGylated Fab′ Fragment against Tumor Necrosis Factor for the Treatment of Crohn Disease

(2008) Tim Bourne et al.   BIODRUGS